AR067903A1 - METHOD TO TREAT STRESSED DEPRESSION - Google Patents

METHOD TO TREAT STRESSED DEPRESSION

Info

Publication number
AR067903A1
AR067903A1 ARP080103495A ARP080103495A AR067903A1 AR 067903 A1 AR067903 A1 AR 067903A1 AR P080103495 A ARP080103495 A AR P080103495A AR P080103495 A ARP080103495 A AR P080103495A AR 067903 A1 AR067903 A1 AR 067903A1
Authority
AR
Argentina
Prior art keywords
patient
depression
gaboxadol
abnormal
levels
Prior art date
Application number
ARP080103495A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR067903A1 publication Critical patent/AR067903A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente se refiere a un método para el tratamiento de la depresion que comprende administrar una cantidad eficaz terapéutica de gaboxadol a un paciente, donde los niveles de uno o más marcadores inflamatorios en dicho paciente están aumentados o son anormales. Se refiere además a un método para el tratamiento de la depresion mediada por estrés que comprende administrar una cantidad eficaz para uso terapéutico de gaboxadol a un paciente, donde los niveles de uno o más marcadores inflamatorios en dicho paciente están aumentados o son anormales. Reivindicacion 11: El método de acuerdo con cualquiera de las reivindicaciones 1-10 donde al paciente se le administra adicionalmente una cantidad eficaz terapéutica de escitalopram o su sal aceptable para uso farmacéutico.This refers to a method for the treatment of depression comprising administering an effective therapeutic amount of gaboxadol to a patient, where the levels of one or more inflammatory markers in said patient are increased or abnormal. It also refers to a method for the treatment of stress-mediated depression that comprises administering an effective amount for therapeutic use of gaboxadol to a patient, where the levels of one or more inflammatory markers in said patient are increased or abnormal. Claim 11: The method according to any of claims 1-10 wherein the patient is additionally administered an effective therapeutic amount of escitalopram or its salt acceptable for pharmaceutical use.

ARP080103495A 2007-08-13 2008-08-11 METHOD TO TREAT STRESSED DEPRESSION AR067903A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701154 2007-08-13

Publications (1)

Publication Number Publication Date
AR067903A1 true AR067903A1 (en) 2009-10-28

Family

ID=39798236

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103495A AR067903A1 (en) 2007-08-13 2008-08-11 METHOD TO TREAT STRESSED DEPRESSION

Country Status (4)

Country Link
AR (1) AR067903A1 (en)
CL (1) CL2008002368A1 (en)
TW (1) TW200920358A (en)
WO (1) WO2009021521A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2007112C2 (en) * 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
IN2014MN01780A (en) 2012-02-09 2015-07-03 Memed Diagnostics Ltd
EP3699930B1 (en) 2014-08-14 2024-02-07 MeMed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN107209184B (en) * 2014-12-11 2020-04-24 米密德诊断学有限公司 Marker combinations for diagnosing multiple infections and methods of use thereof
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
KR20230050474A (en) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. Methods and compositions for treatment of epileptic disorders
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN111201022A (en) * 2017-08-04 2020-05-26 奥维德医疗公司 Use of gaboxadol for treating diabetes and related conditions
US20220008398A1 (en) 2018-11-21 2022-01-13 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (en) 2018-12-17 2021-09-21 奥维德医疗公司 Use of gaboxadol for treating non-24hour sleep-wake disorders
IL293924A (en) 2019-12-18 2022-08-01 Ovid Therapeutics Inc Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
KR20230028244A (en) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. Cyclic deuterated gaboxadol and its use for the treatment of mental disorders
CN113730439A (en) * 2021-09-09 2021-12-03 陕西中鸿瑞康健康管理有限公司 Stem cell factor freeze-dried powder capable of reducing triglyceride and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05013016A (en) * 2003-06-25 2006-03-02 Lundbeck & Co As H Aboxadol for treating depression and other affective disorders.
WO2006053556A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases

Also Published As

Publication number Publication date
CL2008002368A1 (en) 2009-01-02
TW200920358A (en) 2009-05-16
WO2009021521A3 (en) 2009-04-23
WO2009021521A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
AR067903A1 (en) METHOD TO TREAT STRESSED DEPRESSION
CL2011000916A1 (en) Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
UY32989A (en) CONCENTRATED THERAPEUTIC PHOSPHOLIPID COPOSITIONS
SV2009003299A (en) USED DIHYDROPIRIDINE DERIVATIVES AS INHIBITORS OF PROTEIN QUINASE
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
CL2013000304A1 (en) Compounds derived from prostaglandin e2 inhibitor 2-arylamino-benzimidazoles (mpges-1); pharmaceutical composition that includes them; intermediary compounds; use in the treatment of inflammatory diseases and / or associated conditions, in particular pain.
CR11510A (en) USE OF A GAMMA-SECRETASE INHIBITOR FOR CANCER TREATMENT
EA200870254A1 (en) METHOD OF TREATING INFLAMMATORY DISEASES
NI201000105A (en) DOSAGE REGIME ASSOCIATED WITH INJECTABLE, LONG-ACTING PALIPERIDONE ESTERS.
BR112012004806B8 (en) immunogenic compositions that include modulators of tlr activity, method to increase the effectiveness of said composition and use
CO6531463A2 (en) COMBINATIONS OF A PI3K INHIBITOR AND A MEK INHIBITOR
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
BRPI0919020A2 (en) USE OF ENRICHED MONOCYTE LINE CELLS TO TREAT ISCHEMIA AND TO TREAT ANGINA PECTORIS
AR083395A1 (en) NMU PEPTIDIC DERIVATIVE (NEUROMEDINA U) WITH ELEVATED ANORECTIC EFFECT
NI200800169A (en) USE OF BENZO-FUSED HETEROCYCLIC SULFAMID DERIVATIVES FOR THE TREATMENT OF PAIN
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
GT200800307A (en) 18-METIL-19-NOR-ANDROST-4-EN-17,17-ESPIROETERES (18-METIL-19-NOR-20-ESPIROX-4-EN-3-ONAS), AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
ECSP13012551A (en) COMBINATION THERAPY TO TREAT HCV INFECTION.
AR093182A1 (en) METHOD TO TREAT OVERWEIGHT OR OBESITY
AR062401A1 (en) USE OF DERIVATIVES OF 2,5-DIHYDROXIBENCEN TO TREAT DERMATITIS
DOP2013000131A (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND A MEK INHIBITOR
EA200970127A1 (en) MODULATOR OF GLUCOCORTICOSTEROID RECEPTORS AND METHODS OF ITS APPLICATION
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
UY31143A1 (en) DERIVATIVES OF [1,10] -FENANTROLINE FOR THE TREATMENT OF NEURODEGENERATIVE OR HEMATOLOGICAL DISEASES
AR111697A2 (en) OPHTHALM COMPOSITION FOR THE TREATMENT OF EYE ALLERGIES

Legal Events

Date Code Title Description
FB Suspension of granting procedure